Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00505-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Jon B Bruss und 2 weiteren Autor:innen. Beteiligte Einrichtung: Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Renal Insufficiency. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spero Therapeutics, Inc..
Abstract (Originalsprache)
SPR206 is a novel polymyxin derivative with potent in vitro activity against susceptible and multidrug-resistant strains of Acinetobacter baumannii , Pseudomonas aeruginosa , Klebsiella pneumoniae , Escherichia coli , and Enterobacter species. SPR206 is eliminated renally. The safety, tolerability, and pharmacokinetics (PK) of SPR206 were evaluated in healthy subjects with normal renal function (Cohort 1) and subjects with varying degrees of renal impairment (RI) (Cohorts 2–4) or end-stage renal disease (ESRD) on hemodialysis (HD) (Cohort 5). Subjects in Cohorts 1–4 received a 100-mg intravenous (IV) dose of SPR206. Subjects in Cohort 5 received a 100-mg IV dose within 2 h after HD on day 1 and 1 h before HD on day 5. Safety and PK analyses included 37 subjects. Mostly mild but no serious treatment-related adverse events were reported. Systemic exposure to SPR206 increased as renal function decreased, with mean area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC 0–last ) values 39% to 239% greater in subjects with RI vs healthy subjects. Mean plasma clearance (CL) of SPR206 decreased with decreasing renal function (29% to 76% lower vs healthy subjects). In subjects with ESRD, AUC 0–last decreased by 51%, and CL increased by 92% for dialyzed vs nondialyzed conditions. SPR206 was excreted in urine within 12 h in healthy subjects and subjects with mild RI (Cohort 2) but was prolonged in those with moderate and severe RI (Cohorts 3 and 4, respectively). In summary, SPR206 was generally safe and well tolerated, and the PK of SPR206 was well characterized in subjects with RI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA.
ORCID-Profile: Kamal A Hamed
Förderung
- Spero Therapeutics, Inc.
Zitieren
APA
Bruss, J. B., Bader, J., & Hamed, K. A. (2023). Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00505-23
Vancouver
Bruss JB, Bader J, Hamed KA. Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00505-23
BibTeX
@article{Bruss2023,
author = {Bruss, Jon B and Bader, Justin and Hamed, Kamal A},
title = {Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00505-23}
}
EUVIMED